Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Dental Implants Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 07-06-2019
Market Overview
The dental implants market is majorly driven by a rising geriatric population, incidences of dental diseases, increasing demand for cosmetic dentistry, and increasing application of CAD/CAM technologies.
Over the last decade, the major focus on dentistry has been toward dental innovations to improve oral health, through a combination of engineering, art, science, and technology. Computer aided design/computer aided milling (CAD/CAM) is a technological innovation that has revolutionized dental care and patient experience. A structurally-damaged tooth, by decay or trauma, should be crowned or capped for it to function properly and avoid infections. A crown is a durable covering that is custom-made, usually in a dental laboratory, to fit over the entire tooth. CAD/CAM allows the manufacture of crowns immediately within the clinic or hospital. The machine makes it possible to fabricate laboratory-grade crowns and other dental restorations in minutes, whereas, the traditional crowns take two to three visits, in addition to many weeks of waiting. These crown restorations not only save time but also are as successful as traditional crowns, if not more, with their bacteria-static properties. Other technological advances (such as CEREC crowns that use CAD and can be placed in minutes, digital X-rays, non-mercury fillings, intraoral cameras, perio protect, DIAGNOdent, laser dentistry, and isolite, are also being adopted globally, thereby driving the dental implant market.
Scope of the Report
As per the scope of this report, the term dental implants signifies artificial replacements for tooth roots, which can be surgically inserted in the jawbone. Dental implants have two major parts, namely, fixture and abutment, both of which are usually manufactured with zirconium and titanium.
Key Market Trends
Zirconium Implant segment is Expected to grow fastest during the Forecast Period
The titanium segment held a maximum share in 2018 as most of the implants are developed from titanium. The biocompatible nature of the titanium makes it suitable to be used for implant. These implants are made as one-piece or two-pieces, which offer better features as they can support overdentures.
The zirconium segment is forecasted to show significant growth during the forecast period. This growth can be attributed to the growing adoption of these implants, as they can be manufactured in different sizes (length and width), which enables choosing of implants as per the patient’s bone size.
North America holds the Largest Market Share of Dental Implants Market Currently and is Believed to Follow the Same Trend over the Forecast Period
The North American dental implants market dominated the global market, and is estimated to show a similar trend during the forecast period. This growth is primarily attributed to a rise in geriatric population with oral problems. According to the United States’ Centers for Disease Control and Prevention (CDC), about one-quarter of Americans, aged 65 and older, have lost their teeth. One-third have untreated tooth decay, even though poor dental health is linked to heart problems and other health concerns. The US government has also launched an affordable care plan to cover the dental services for children. Thus, an increasing number of dental problems and governmental efforts to improve the healthcare sector for the citizens are expected to augment the market for dental implants in North America.
Competitive Landscape
The dental implants market is moderately competitive, and consists of a few major players. The companies are implementing certain strategic initiatives, such as the mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. For instance, Zimmer Dental introduced Zimmer Zfx CAD/CAM Abutments in titanium in partnership with Zfx to expand its global presence in digital dentistry by providing complete dental solutions.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population and Incidences of Dental Diseases
4.2.2 Increasing Demand for Cosmetic Dentistry
4.2.3 Increasing Application of CAD/CAM Technologies
4.3 Market Restraints
4.3.1 Reimbursement Issues and High Cost of Dental Implants
4.3.2 Lack of Awareness in Developing Markets
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Part
5.1.1 Fixture
5.1.1.1 Endosteal Implant
5.1.1.2 Subperiosteal Implant
5.1.1.3 Transosteal Implant
5.1.1.4 Intramucosal Implant
5.1.2 Abutment
5.2 By Material
5.2.1 Titanium Implant
5.2.2 Zirconium Implant
5.3 By Procedure
5.3.1 Single Stage
5.3.2 Two Stage
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Straumann AG
6.1.2 Dentsply Sirona
6.1.3 Zimmer Biomet
6.1.4 Osstem Implant Co. Ltd
6.1.5 Henry Schein Inc.
6.1.6 Danaher Corporation
6.1.7 Thommen Medical AG
6.1.8 Shofu Dental Corporation
6.1.9 Ivoclar Vivadent, Inc.
6.1.10 Young Innovations, Inc.
6.1.11 3M
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Part
Fixture
Endosteal Implant
Subperiosteal Implant
Transosteal Implant
Intramucosal Implant
Abutment
By Material
Titanium Implant
Zirconium Implant
By Procedure
Single Stage
Two Stage
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
]Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Diabetes Care Devices Market – Growth, Trends, and Forecast (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 17-06-2019
Market Overview
The global diabetes care devices market is expected to register a CAGR of about 6.8% during the forecast period (2019 – 2023).
Asia-Pacific is anticipated to dominate the market during the forecast period, owing to rising prevalence of obesity in the region.
There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.
Technological innovations and advances give much convenience in measuring the blood glucose levels. One such advancement in monitoring the blood glucose levels is established with continuous glucose monitoring devices.
Scope of the Report
The global diabetes care devices market is segmented by management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood glucose (hospital and personal use) and continuous glucose monitoring), and geography.
Key Market Trends
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes among adults of over 18 years accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh-leading cause of death by 2030.
The growing prevalence of diabetes is the major driver for the global diabetes care devices market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market for diabetes care devices.
North America to Dominate the Monitoring Devices Segment
The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles.
Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness regarding diabetic care.
Competitive Landscape
There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of few strategic outcomes include:
In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for diabetics aged between aged between 14-75 years.
In January 2018, Abbott announced that the FreeStyleLibre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, was available to Medicare patients in the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Monitoring Devices
5.1.1 Self-Monitoring Blood Glucose Devices
5.1.1.1 By Component (Value and Volume, 2012 – 2024)
5.1.1.1.1 Glucometer Devices
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.1.2 By End User
5.1.1.2.1 Hospital (Value and Volume, 2012 – 2024)
5.1.1.2.1.1 Glucometer Devices
5.1.1.2.1.2 Test Strips
5.1.1.2.1.3 Lancets
5.1.1.2.2 Personal (Value and Volume, 2012 – 2024)
5.1.1.2.2.1 Glucometer Devices
5.1.1.2.2.2 Test Strips
5.1.1.2.2.3 Lancets
5.1.2 Continuous Blood Glucose Monitoring
5.1.2.1 By Component (Value and Volume, 2012 – 2024)
5.1.2.1.1 Sensors
5.1.2.1.2 Receivers
5.2 Management Devices
5.2.1 Insulin Pump
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens
5.2.5 Jet Injectors
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012 – 2024)
5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.1.2 Canada (Value and Volume, 2012 – 2024)
5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.1.3 Rest of North America (Value and Volume, 2012 – 2024)
5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012 – 2024)
5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.2 Germany (Value and Volume, 2012 – 2024)
5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.3 Italy (Value and Volume, 2012 – 2024)
5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.4 Spain (Value and Volume, 2012 – 2024)
5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.5 United Kingdom (Value and Volume, 2012 – 2024)
5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.6 Russia (Value and Volume, 2012 – 2024)
5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.7 Rest of Europe (Value and Volume, 2012 – 2024)
5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012 – 2024)
5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3.2 Brazil (Value and Volume, 2012 – 2024)
5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3.3 Rest of Latin America (Value and Volume, 2012 – 2024)
5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012 – 2024)
5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.2 South Korea (Value and Volume, 2012 – 2024)
5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.3 China (Value and Volume, 2012 – 2024)
5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.4 India (Value and Volume, 2012 – 2024)
5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.5 Australia (Value and Volume, 2012 – 2024)
5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.6 Vietnam (Value and Volume, 2012 – 2024)
5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.7 Malaysia (Value and Volume, 2012 – 2024)
5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.8 Indonesia (Value and Volume, 2012 – 2024)
5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.8.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.8.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.9 Philippines (Value and Volume, 2012 – 2024)
5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.9.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.9.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.10 Thailand (Value and Volume, 2012 – 2024)
5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.10.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.10.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.11.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.11.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5 Middle East & Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012 – 2024)
5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.2 Iran (Value and Volume, 2012 – 2024)
5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.3 Egypt (Value and Volume, 2012 – 2024)
5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.4 Oman (Value and Volume, 2012 – 2024)
5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.5 South Africa (Value and Volume, 2012 – 2024)
5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 – 2024)
5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Arkray
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
7.1.10 Acon
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Dexcom
7.2.5 Medtronic
7.2.6 Novo Nordisk
7.2.7 Eli Lilly
7.2.8 Sanofi
7.2.9 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Monitoring Devices
Self-Monitoring Blood Glucose Devices
By Component (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
Personal (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
Continuous Blood Glucose Monitoring
By Component (Value and Volume, 2012 – 2024)
Sensors
Receivers
Management Devices
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Cartridges
Disposable Pens
Jet Injectors
Geography
North America
United States (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Canada (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of North America (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Europe
France (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Germany (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Italy (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Spain (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
United Kingdom (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Russia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Europe (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Latin America
Mexico (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Brazil (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Latin America (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Asia-Pacific
Japan (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
South Korea (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
China (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
India (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)Australia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Vietnam (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Malaysia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Indonesia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Philippines (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Thailand (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Iran (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Egypt (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Oman (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
South Africa (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Middle & Africa (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Diabetes Care Drugs Market (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 12-06-2019
Market Overview
The market size, in 2017, for the global diabetes drugs market was registered to be USD 67,510.43 million, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
North America dominates the market, followed by Asia-Pacific.
Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body’s cells do not respond properly to insulin (known as Type 2 diabetes), or both.
Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.
Scope of the Report
The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.
Key Market Trends
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, the growing prevalence of obesity, and technological advancements are further driving the market.
The United States Leads the Diabetes Drugs Market in North America
In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.
Competitive Landscape
There have been constant innovations driven by manufacturers to compete and struggle in the market.
Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.
In 2015 and 2016, Lantus global sales were down by 11%, due to competition from other new drugs, biosimilars, and its own brand Toujeo.
September 2017: Insulin Tregopil, the first Oral Insulin, was under development by Biocon India, which is supported by JDRF.
March 2017: Zynquista (Sotagliflozin) was the first oral anti-diabetic drug approved in the United States for use by adults with Type 1 diabetes.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Monitoring Devices
5.1.1 Self-Monitoring Blood Glucose Devices
5.1.1.1 By Component (Value and Volume, 2012 – 2024)
5.1.1.1.1 Glucometer Devices
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.1.2 By End User
5.1.1.2.1 Hospital (Value and Volume, 2012 – 2024)
5.1.1.2.1.1 Glucometer Devices
5.1.1.2.1.2 Test Strips
5.1.1.2.1.3 Lancets
5.1.1.2.2 Personal (Value and Volume, 2012 – 2024)
5.1.1.2.2.1 Glucometer Devices
5.1.1.2.2.2 Test Strips
5.1.1.2.2.3 Lancets
5.1.2 Continuous Blood Glucose Monitoring
5.1.2.1 By Component (Value and Volume, 2012 – 2024)
5.1.2.1.1 Sensors
5.1.2.1.2 Receivers
5.2 Management Devices
5.2.1 Insulin Pump
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens
5.2.5 Jet Injectors
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012 – 2024)
5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.1.2 Canada (Value and Volume, 2012 – 2024)
5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.1.3 Rest of North America (Value and Volume, 2012 – 2024)
5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012 – 2024)
5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.2 Germany (Value and Volume, 2012 – 2024)
5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.3 Italy (Value and Volume, 2012 – 2024)
5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.4 Spain (Value and Volume, 2012 – 2024)
5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.5 United Kingdom (Value and Volume, 2012 – 2024)
5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.6 Russia (Value and Volume, 2012 – 2024)
5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.7 Rest of Europe (Value and Volume, 2012 – 2024)
5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012 – 2024)
5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3.2 Brazil (Value and Volume, 2012 – 2024)
5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3.3 Rest of Latin America (Value and Volume, 2012 – 2024)
5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012 – 2024)
5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.2 South Korea (Value and Volume, 2012 – 2024)
5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.3 China (Value and Volume, 2012 – 2024)
5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.4 India (Value and Volume, 2012 – 2024)
5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.5 Australia (Value and Volume, 2012 – 2024)
5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.6 Vietnam (Value and Volume, 2012 – 2024)
5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.7 Malaysia (Value and Volume, 2012 – 2024)
5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.8 Indonesia (Value and Volume, 2012 – 2024)
5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.8.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.8.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.9 Philippines (Value and Volume, 2012 – 2024)
5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.9.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.9.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.10 Thailand (Value and Volume, 2012 – 2024)
5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.10.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.10.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.11.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.11.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5 Middle East & Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012 – 2024)
5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.2 Iran (Value and Volume, 2012 – 2024)
5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.3 Egypt (Value and Volume, 2012 – 2024)
5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.4 Oman (Value and Volume, 2012 – 2024)
5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.5 South Africa (Value and Volume, 2012 – 2024)
5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 – 2024)
5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Arkray
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
7.1.10 Acon
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Dexcom
7.2.5 Medtronics
7.2.6 Novo Nordisk
7.2.7 Eli Lilly
7.2.8 Sanofi
7.2.9 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Monitoring Devices
Self-Monitoring Blood Glucose Devices
By Component (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
Personal (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
Continuous Blood Glucose Monitoring
By Component (Value and Volume, 2012 – 2024)
Sensors
Receivers
Management Devices
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Cartridges
Disposable Pens
Jet Injectors
Geography
North America
United States (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Canada (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of North America (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Europe
France (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Germany (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Italy (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Spain (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
United Kingdom (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Russia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Europe (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Latin America
Mexico (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Brazil (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Latin America (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Asia-Pacific
Japan (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
South Korea (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
China (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
India (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Australia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Vietnam (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Malaysia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Indonesia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Philippines (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Thailand (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Iran (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Egypt (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Oman (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
South Africa (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Middle & Africa (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Diagnostic Imaging Market – Segmented by Type (X-Ray, MRI, Nuclear Medicine, Ultrasound, Tomography, Tactile Imaging, Thermography & Others), By Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology), By Geography – Analysis and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| Unknown | Published: 21-06-2019 |
- Healthcare
- Mordor Intelligence
- pages
- Published: 21-06-2019
Diagnostic Imaging Market
The market has been estimated at USD XX billion for the year 2016 and is projected to reach USD XX billion by the end of 2021 at a CAGR of XX% during the forecast period from 2016 to 2021.
Medical imaging is the process of making a visual representation of the interior of the body for medical intervention. These instruments help in establishing a database of normal anatomy and physiology of internal organs so that any abnormality can be noticed immediately. The ability to create pictures of a patient’s internal anatomy and convert them to film through diagnostic imaging has revolutionized the way many diseases and injuries are detected, diagnosed, and treated. This market has applications in various medical fields like cardiology, oncology, neurology, and orthopedics. Globally, most of the industrialized countries are spending a large part of their GDP on healthcare requirements. The US is set to spend nearly 20% of its GDP on healthcare by 2017, a higher percentage than any other industrialized nation.
Wider adoption of cloud technologies and adoption of new advanced technologies play a major role in improving the market economy. Increasing aging populations and increased incidence of chronic diseases are also key factors driving the market. According to the National Institutes of Health, patients aged 65 and older undergo diagnostic imaging at two or more times the rate of younger people. Women also tend to use slightly higher rates of imaging than men. In spite of these factors driving the market, there are other factors constraining the growth of the market. Expensive procedures & equipment, side effects of diagnostic imaging procedures and saturation in the developed regions are the major challenges faced by the diagnostic imaging equipment market.
There are several new developments afoot in the medical imaging world. Imaging science is a dynamic, evolving field of multi- and interdisciplinary activities with a lot of scope and importance. Due to the increasing need to operate more efficiently and productively, medical imaging facilities will increasingly turn towards data analytics. There will be growing interest and demand for analytics solutions. PACS, RIS, and dictation systems are driving this market currently and are anticipated to emerge economically in coming years.
The market is segmented based on type (X-ray, MRI, nuclear medicine, ultrasound, tomography, tactile imaging, photoacoustic imaging, thermography, elastography, echocardiography, and functional near infrared spectroscopy). A few segments are sub-divided based on portability, structure, technology and resolution.
Tomosynthesis is another prominently used method. According to the Radiological Society of North America, tomosynthesis, or 3D mammography increases cancer detection and reduces the instances of the patient being called for further tests. 3D imaging is expected to grow in all markets during the forecast period. Manufacturers are showing a keen interest in improving image quality by exploiting new technologies and producing new instruments or novel techniques to achieve images with higher spatial resolution. Imaging will continue to advance and provide an essential set of tools for clinical research, drug development, disease diagnosis, treatment and assessing treatment response.
Based on geography, the global diagnostic imaging market is divided into North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Currently, North America dominates the market with nearly 20% of the gross domestic product spent on healthcare by the USA. Asia-Pacific is a market that is expected to grow at a faster rate, owing to the rapidly aging population and increase in the chronic disease population.
Medical imaging technology is a rapidly changing field, and healthcare organizations have multiple options for new acquisitions. Many players in this market are trying to expand their product portfolio in order to top the global market. A few companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market.
Key Deliverables in the Study
Market analysis for the diagnostic imaging market, with region specific assessments and competition analysis on the global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the global diagnostic imaging market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Medical Imaging Industry Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Rise in the Prevalence of Chronic Diseases
6.1.2 Increased Adoption of Advanced Technologies in Medical Imaging
6.1.3 Increase in the Geriatric Population
6.2 Restraints
6.2.1 Expensive Procedures and Equipment
6.2.2 Side Effects of Diagnostic Imaging
6.2.3 Slower Growth in Developed Regions
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Medical Imaging Market – Product Type
7.1.1 X-Ray Equipment
7.1.1.1 Stationary
7.1.1.2 Portable
7.1.2 Fluoroscopy
7.1.2.1 Fixed Fluoroscope
7.1.2.2 Mobile Fluoroscope
7.1.3 MRI
7.1.3.1 Closed Systems
7.1.3.2 Open Systems
7.1.4 Ultrasound
7.1.5 Computed Tomography
7.1.6 Other Imaging Modalities
7.2 Medical Imaging Market – By Application
7.2.1 Cardiology
7.2.2 Oncology
7.2.3 Neurology
7.2.4 Orthopedics
7.2.5 Gastroenterology
7.2.6 Gynecology
7.2.7 Other Applications
7.3 Medical Imaging Market – By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisitions Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Carestream Health Inc.
9.2 Esoate SpA
9.3 Fujifilm Holding
9.4 GE Healthcare
9.5 Hitachi Medical Systems
9.6 Hologic Corporation
9.7 Philips Healthcare
9.8 Shimadzu Medical
9.9 Siemens Healthcare
9.10 Canon Medical Systems Corporation
*List not Exhaustive
10. Future of the Marke
Market Segmentation
Medical Imaging Market – Product Type
X-Ray Equipment
Stationary
Portable
Fluoroscopy
Fixed Fluoroscope
Mobile Fluoroscope
MRI
Closed Systems
Open Systems
Ultrasound
Computed Tomography
Other Imaging Modalities
Medical Imaging Market – By Application
Cardiology
Oncology
Neurology
Orthopedics
Gastroenterology
Gynecology
Other Applications
Medical Imaging Market – By Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of the Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Diagnostic Radiopharmaceuticals & Contrast Media Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 10-06-2019
Market Overview
The global diagnostic radiopharmaceuticals and contrast media market is growing at a steady rate, due to factors, such as technological developments, increasing diagnostic applications in various diseases, government support, and rising cases of chronic diseases. Also, factors, such as shorter half-life of radiopharmaceuticals, stringent regulatory framework, and high capital investment, are expected to hinder the market growth.
The development in the minimally invasive therapeutic procedures has encouraged the usage of imaging equipment. This increase in the demand for image guidance has propelled the market. Additionally, medical imaging has witnessed numerous advancements in recent times. The emerging technologies help in enhancing the resolution and quality of the medical images, in turn, propelling the demand for contrast media and diagnostic radiopharmaceuticals. Rising cancer cost is another factor, which is impacting healthcare costs. The government is taking several initiatives for better cancer management. These initiatives are likely to affect the imaging industry, as they give the multinational companies a potential place to make significant investments.
Scope of the Report
Radiopharmaceuticals are a group of pharmaceutical drugs that have radioactivity and can be used as diagnostics and therapeutic agents. Contrast media is the substance used to enhance the contrast of an image, hence, making an image more detailed and apparent. Contrast media is increasingly being used in various medical imaging techniques, such as MRI and CT. This report analyzes and discusses the global radiopharmaceuticals and contrast media market.
Key Market Trends
Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance
The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died from CVDs. SPECT, which stands for single photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from an irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the market over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. The US diagnostic radiopharmaceuticals and contrast media market is anticipated to continue its expansion over the forecast period. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and they have set a string trend in the industry to continue to find more efficient, accurate, and safe agents.
The contrast media sales are expected to increase in the United States in the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are likely to have a considerable growth rate. Diagnostic radioisotopes are a significant component of the US economy. Increase in chronic cardiac and neurological diseases is the primary driving factor for the market growth in the United States. Hence, the North American diagnostic radiopharmaceuticals and contrast media market is expected to retain its dominance over the forecast period.
Competitive Landscape
The presence of major market players, such as Bayer AG, GE Healthcare, Cardinal Health Inc., Nordion Inc., and Siemens Healthineers, is in turn, increasing the overall competitive rivalry of the market. The scarce presence of few companies operating in this sector, along with factors, such as powerful competitive strategy and strong market foothold, is resulting in the low score of the market, in terms of competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technology Advancements in Medical Imaging
4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
4.2.3 High Prevalence of Cancers and Cardiac Diseases
4.3 Market Restraints
4.3.1 High Costs of the Techniques- Not Easily Affordable
4.3.2 Limited Health Insurance Coverage
4.3.3 Short Half-life of Radiopharmaceuticals
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Radiopharmaceuticals
5.1.1 By Type of Imaging Modality
5.1.1.1 SPECT
5.1.1.1.1 Tc-99
5.1.1.1.2 Tl-201
5.1.1.1.3 Ga-67
5.1.1.1.4 I-123
5.1.1.1.5 Other SPECTs
5.1.1.2 PET
5.1.1.2.1 F-18
5.1.1.2.2 Rb-82
5.1.1.2.3 Other PETs
5.1.2 By Application
5.1.2.1 Diagnostic Application
5.1.2.1.1 SPECT Applications
5.1.2.1.1.1 Cardiology
5.1.2.1.1.2 Neurology
5.1.2.1.1.3 Thyroid
5.1.2.1.1.4 Other SPECT Applications
5.1.2.1.2 PET Application
5.1.2.1.2.1 Oncology
5.1.2.1.2.2 Cardiology
5.1.2.1.2.3 Neurology
5.1.2.1.2.4 Other PET Applications
5.1.2.2 Therapeutic Application
5.1.2.2.1 Thyroid
5.1.2.2.2 Lymphoma
5.1.2.2.3 Endocrine Tumors
5.1.2.2.4 Other Therapeutic Applications
5.2 Contrast Media
5.2.1 By Application
5.2.1.1 Ionizing Radiation-based Radioimaging
5.2.1.2 Non-Ionizing Radiation-based Radioimaging
5.2.2 By Procedure
5.2.2.1 X-ray/Computed Tomography (CT)
5.2.2.1.1 Iodinated Contrast Media Ionic
5.2.2.1.2 Iodinated Contrast Media Non-Ionic
5.2.2.1.3 Barium-based Contrast Media
5.2.2.2 Magnetic Resonance Imaging (MRI)
5.2.2.2.1 Gadolinium-based Contrast Media
5.2.2.2.2 Other Magnetic Resonance Imaging
5.2.2.3 Ultrasound
5.2.3 By Indication
5.2.3.1 Cardiovascular Disease
5.2.3.2 Oncology
5.2.3.3 Gastrointestinal
5.2.3.4 Disorders
5.2.3.5 Neurological
5.2.3.6 Disorders
5.2.3.7 Other Indications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bioclinica
6.1.2 Bio-Optronics Inc.
6.1.3 DATATRAK International Inc.
6.1.4 ERT Clinical
6.1.5 IBM Watson Health
6.1.6 Medidata Solutions Inc.
6.1.7 MedNet Solutions Inc.
6.1.8 Oracle Corporation
6.1.9 Parexel International Corporation
6.1.10 ArisGlobal
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Radiopharmaceuticals
By Type of Imaging Modality
SPECT
Tc-99
Tl-201
Ga-67
I-123
Other SPECTs
PET
F-18
Rb-82
Other PETs
By Application
Diagnostic Application
SPECT Applications
Cardiology
Neurology
Thyroid
Other SPECT Applications
PET Application
Oncology
Cardiology
Neurology
Other PET Applications
Therapeutic Application
Thyroid
Lymphoma
Endocrine Tumors
Other Therapeutic Applications
Contrast Media
By Application
Ionizing Radiation-based Radioimaging
Non-Ionizing Radiation-based Radioimaging
By Procedure
X-ray/Computed Tomography (CT)
Iodinated Contrast Media Ionic
Iodinated Contrast Media Non-Ionic
Barium-based Contrast Media
Magnetic Resonance Imaging (MRI)
Gadolinium-based Contrast Media
Other Magnetic Resonance Imaging
Ultrasound
By Indication
Cardiovascular Disease
Oncology
Gastrointestinal
Disorders
Neurological
Disorders
Other Indications
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018 and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.
Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.
Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
Scope of the Report
The DPP-4 inhibitors market is segmented by brands and covers the following brands: Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented into five regions: North America, Asia-Pacific, Middle East & Africa, Latin America, and Europe.
Key Market Trends
The Tradjenta Market will Surpass Merck’s Januvia During the Forecast Period
The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market.
North America Holds the Highest Market Share
The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.
Competitive Landscape
Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position until 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.1 Januvia (Sitagliptin)
5.1.1.2 Onglyza (Saxagliptin)
5.1.1.3 Tradjenta (Linagliptin)
5.1.1.4 Vipidia/Nesina (Alogliptin)
5.1.1.5 Galvus (Vildagliptin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Merck And Co.
7.1.2 AstraZeneca
7.1.3 Bristol Myers Squibb
7.1.4 Novartis
7.1.5 Takeda Pharmaceuticals
7.1.6 Eli Lilly
7.1.7 Boehringer Ingelheim
7.2 Company Share Analysis
7.2.1 Merck And Co.
7.2.2 AstraZeneca
7.2.3 Takeda Pharmaceuticals
7.2.4 Novartis
7.2.5 Eli Lilly & Boehringer Ingelheim
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Geography
North America
United States (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Canada (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of North America (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Europe
France (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Germany (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Italy (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Spain (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
United Kingdom (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Russia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Europe (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Latin America
Mexico (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Brazil (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Latin America (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Korea (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
China (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
India (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Australia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Vietnam (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Malaysia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Indonesia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Philippines (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Thailand (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Iran (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Egypt (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Oman (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Middle East & Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)